Skip to content
2000
Volume 22, Issue 1
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Introduction

14-3-3η (eta), an intracellular chaperonin, is elevated in the serum of patients with Rheumatoid Arthritis, a progressive inflammatory “autoimmune” disease that impacts joint function and daily activities. This study aimed to assess 14-3-3η levels in DMARD-naïve Rheumatoid Arthritis patients and analyze its association with TNF-α, MMP-1, RA factor, AC CP, and disease activity.

Methods

A cross-sectional study was conducted on 90 DMARD-naïve RA patients. The clinical evaluation included the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the Disease Activity Score of 28 joints using ESR (DAS28-ESR). Serum levels of RF, ACCP, 14-3-3η, TNF-α, and MMP-1 were measured using ELISA. Mann-Whitney and Spearman correlation tests were applied, with < 0.05 considered statistically significant.

Results

Among 90 RA patients (76 females, 14 males), 68(75.6%) were seropositive. Serum levels of 14-3-3η and TNF-α differed significantly between seropositive and seronegative groups. TNF-α correlated positively with both 14-3-3η (r = 0.397, < 0.001) and MMP-1 (r = 0.284, = 0.007).

Discussion

The correlation between 14-3-3η and TNF-α suggests a possible role for 14-3-3η as an adjunctive biomarker in early RA. While findings are promising, the small sample size and lack of follow-up warrant cautious interpretation. Further longitudinal studies are needed to confirm its clinical utility and integration within composite biomarker models.

Conclusion

Serum 14-3-3η may serve as a supportive biomarker for the diagnosis of early rheumatoid arthritis and assessment of disease activity. Its correlation with TNF-α reflects a potential link to inflammatory burden. Further large-scale, longitudinal studies are needed to confirm its clinical utility.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971375944250811060418
2025-08-15
2026-03-02

  • From This Site

    /content/journals/crr/10.2174/0115733971375944250811060418
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HiranoT. IL-6 in inflammation, autoimmunity and cancer.Int. Immunol.202133312714810.1093/intimm/dxaa07833337480
     [Google Scholar]
  2. KorolkovaA.A. KhizhaV.V. KozlovaD.I. VasilievD.S. MaslyanskyA.L. VavilovaT.V. BallyuzekM.F. RybakovA.V. ShevaldinaM.E. YurievaK.A. 14-3-3η cytokine as a new biomarker to assess rheumatoid arthritis disease activity.J. Evol. Biochem. Physiol.202359114115310.1134/S002209302301012X
     [Google Scholar]
  3. WeiJ.C.C. LeongP.Y. LiuG.Y. Chaperone/scaffolding/adaptor protein 14-3-3η (eta): A diagnostic marker of rheumatoid arthritis.Int. J. Rheum. Dis.202023111439144210.1111/1756‑185X.1400433225576
     [Google Scholar]
  4. MengM. JialinY. YukunZ. HuijunS. MozhenL. Potential anti-rheumatoid arthritis activities and mechanisms of Ganoderma lucidum polysaccharides.Molecules20232862483248310.3390/molecules28062483
     [Google Scholar]
  5. MoudgilK.D. VenkateshaS.H. The anti-inflammatory and immunomodulatory activities of natural products to control autoimmune inflammation.Int. J. Mol. Sci.20222419510.3390/ijms2401009536613560
     [Google Scholar]
  6. AbdiG. JainM. PatilN. UpadhyayB. VyasN. DwivediM. KaushalR.S. 14-3-3 proteins—a moonlight protein complex with therapeutic potential in neurological disorder: In-depth review with Alzheimer’s disease.Front. Mol. Biosci.202411128653610.3389/fmolb.2024.128653638375509
     [Google Scholar]
  7. KasimovaM. AkhmedovaN. XudoynazarovA. An interaction of proteins of the 14-3-3 family with cytoskeletal system. Orig. Med.202211
     [Google Scholar]
  8. FanX. 14-3-3 proteins are on the crossroads of cancer, aging, and age-related neurodegenerative disease.Int J Mol Sci.20192014351810.3390/ijms20143518
     [Google Scholar]
  9. ZhouR. HuW. MaP.X. LiuC. Versatility of 14-3-3 proteins and their roles in bone and joint-related diseases.Bone Res.20241215810.1038/s41413‑024‑00370‑439406741
     [Google Scholar]
  10. ChakravartiR. Immune regulations by 14-3-3: A misty terrain.Immunobiology2021226615214510.1016/j.imbio.2021.15214534628289
     [Google Scholar]
  11. SilvaM.M.B. Targeting 14-3-3 proteins to promote axon regeneration.Thesis McGill University2022
     [Google Scholar]
  12. CovingtonT.R. DeS. Binding partners of 14-3-3 (YWHA) protein isoforms among mammalian species, tissues, and developmental stages.Adv. J. Grad. Res.2021101162210.21467/ajgr.10.1.16‑22
     [Google Scholar]
  13. BarleyE. DeS. Functional influence of 14-3-3 (YWHA) proteins in mammals.Mako. NSU Undergraduat. Student J.2021202112
     [Google Scholar]
  14. BenarrochE. What is the function and relevance of 14-3-3 proteins in neurologic disease?Neurology20251045e21341810.1212/WNL.000000000021341839889260
     [Google Scholar]
  15. KristinaT.V DariaK.I RichardC.B SergeiS.V NikolaiS.N Concatenation of 14-3-3 with partner phosphoproteins as a tool to study their interaction.Sci Rep201991150071500710.1038/s41598‑019‑50941‑3
     [Google Scholar]
  16. ObsilovaV. ObsilT. Structural insights into the functional roles of 14-3-3 proteins.Front. Mol. Biosci.20229101607110.3389/fmolb.2022.101607136188227
     [Google Scholar]
  17. LiuJ. CaoS. DingG. WangB. LiY. ZhaoY. ShaoQ. FengJ. LiuS. QinL. XiaoY. The role of 14-3-3 proteins in cell signalling pathways and virus infection.J. Cell. Mol. Med.20212594173418210.1111/jcmm.1649033793048
     [Google Scholar]
  18. NathanK.G. LalS.K. The multifarious role of 14-3-3 family of proteins in viral replication.Viruses202012443610.3390/v1204043632294919
     [Google Scholar]
  19. MunierC.C. OttmannC. PerryM.W.D. 14-3-3 modulation of the inflammatory response.Pharmacol. Res.202116310523610.1016/j.phrs.2020.10523633053447
     [Google Scholar]
  20. ShawkyA.D. MostafaE.R. Abd ElnabyAmira Yousef WaseemN.D. Will 14-3-3η be a new diagnostic and prognostic biomarker in rheumatoid arthritis? A prospective study of its utility in early diagnosis and response to treatment.Autoimmune Dis202220221497748149774810.1155/2022/149774835096510
     [Google Scholar]
  21. YokotaK. SatoK. MiyazakiT. AizakiY. TanakaS. SekikawaM. KozuN. KadonoY. OdaH. MimuraT. Characterization and function of tumor necrosis factor and interleukin-6–induced osteoclasts in rheumatoid arthritis.Arthritis Rheumatol.20217371145115410.1002/art.4166633512089
     [Google Scholar]
  22. Doğanİ. KorA. GüvenS.C. Fırat OğuzE. BaşerS. AtalarE. MaraşY. ErelÖ. ErtenŞ. 14–3-3 η ETA protein as a potential marker of joint damage in gout.Clin. Biochem.202311811061110.1016/j.clinbiochem.2023.11061137429510
     [Google Scholar]
  23. DarwishN.F. HablasS.A. BaiomyN.N. RagehE.S.M.H. Evaluation of serum14-3-3η protein and Sema3A levels in rheumatoid arthritis: Diagnostic and prognostic value.Egypt. Rheumatol. Rehabil.20204714310.1186/s43166‑020‑00044‑z
     [Google Scholar]
  24. ZengT. TanL. 14-3-3η protein: A promising biomarker for rheumatoid arthritis.Biomarkers Med.201812891792510.2217/bmm‑2017‑038530022679
     [Google Scholar]
  25. KilbornS. BukhariM. AB0302 The role of the biomarker 14–3–3 eta in rheumatoid arthritis: A review.Ann. Rheum. Dis.201877132910.1136/annrheumdis‑2018‑eular.6614
     [Google Scholar]
  26. MaktubaT.N.D. 14-3-3(ETA) protein as a new biomarker in rheumatoid arthritis.Int. J. Adv. Sci. Technol20202918711877
     [Google Scholar]
  27. RaduA.F. BungauS.G. Management of rheumatoid arthritis: An overview.Cells20211011285710.3390/cells1011285734831081
     [Google Scholar]
  28. SiddleH.J. BradleyS.H. AndersonA.M. MankiaK. EmeryP. RichardsS.H. Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice.Br. J. Gen. Pract.20237372915215410.3399/bjgp23X73232136997210
     [Google Scholar]
  29. HavilleS. DeaneK.D. Pre-RA: Can early diagnosis lead to prevention?Best Pract. Res. Clin. Rheumatol.202236110173710.1016/j.berh.2021.10173734991984
     [Google Scholar]
  30. PetrovskáN. PrajzlerováK. VencovskýJ. ŠenoltL. FilkováM. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis.Autoimmun. Rev.202120510279710.1016/j.autrev.2021.10279733746022
     [Google Scholar]
  31. MuellerA.L. PayandehZ. MohammadkhaniN. MubarakS.M.H. ZakeriA. Alagheband BahramiA. BrockmuellerA. ShakibaeiM. Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies.Cells20211011301710.3390/cells1011301734831240
     [Google Scholar]
  32. LönnblomE. Autoantibodies to disease-related proteins in joints as novel biomarkers for the diagnosis of rheumatoid arthritis.Arthritis Rheumatol2023757111010.1002/art.42463
     [Google Scholar]
  33. SokolovaM.V. SchettG. SteffenU. Autoantibodies in rheumatoid arthritis: Historical background and novel findings.Clin. Rev. Allergy Immunol.202163213815110.1007/s12016‑021‑08890‑134495490
     [Google Scholar]
  34. ShapiroS.C. Biomarkers in rheumatoid arthritis.Cureus2021135e1506334141507
     [Google Scholar]
  35. RosaJ.E. GarcíaM.V. LuissiA. PieriniF. SabelliM. MollerachF. SorianoE.R. Rheumatoid arthritis patient’s journey: Delay in diagnosis and treatment.J. Clin. Rheumatol.2020267SSuppl. 2S148S15210.1097/RHU.000000000000119631609811
     [Google Scholar]
  36. EbrahimianS. SalamiA. Malek MahdaviA. EsalatmaneshK. KhabbaziA. HajialiloM. Can treating rheumatoid arthritis with disease-modifying anti-rheumatic drugs at the window of opportunity with tight control strategy lead to long-term remission and medications free remission in real-world clinical practice? A cohort study.Clin. Rheumatol.202140114485449110.1007/s10067‑021‑05831‑334164737
     [Google Scholar]
  37. NaeemF. Diagnostic and therapeutic delay in Rheumatoid Arthritis patients: Impact on disease outcome.Pak J Med Sci202134100110.12669/pjms.37.4.3471
     [Google Scholar]
  38. DeaneK.D. HolersV.M. Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift.Arthritis Rheumatol.202173218119310.1002/art.4141732602263
     [Google Scholar]
  39. BergstraS.A. Van Der PolJ.A. RiyaziN. Goekoop-RuitermanY.P.M. KerstensP.J.S.M. LemsW. HuizingaT.W.J. AllaartC.F. Earlier is better when treating rheumatoid arthritis: But can we detect a window of opportunity?RMD Open202061e00124210.1136/rmdopen‑2020‑00124232471854
     [Google Scholar]
  40. SharmaR.H. CojandarajL.A. A review on comparative study of 14-3-3 η protein with conventional serum marker and its role in rheumatoid arthritis.J. Shanghai Jiaotong Uni.2020619883-895
     [Google Scholar]
  41. OthmanM.I. FahmyH. Al-ShahalyM.H. MohammadM.H. Comparison of serum levels of 14-3-3 ETA proteins between rheumatoid arthritis, osteoarthritis and normal controls.Egypt. J. Immunol.202027116917533180398
     [Google Scholar]
  42. YarlagaddaL.D. JacobR. RajasekharD.L. IyyapuK.M. KompellaS.B.S.S. MadrolV.B. SreedeviN.N. KhanS.A. MohammedN. Evaluation of a new biomarker 14-3-3 Eta protein in diagnosis of rheumatoid arthritis.Indian J. Rheumatol.202015317518010.4103/injr.injr_30_20
     [Google Scholar]
  43. SubediR. MisbahA. NajadaA.A. OconA.J. Evaluation of 14-3-3eta protein as a diagnostic biomarker in the initial assessment of inflammatory arthritis.J. Rheum. Dis.202532213013510.4078/jrd.2024.011040134547
     [Google Scholar]
  44. AbduazizovaN. BerdiyevaD. SharapovZ. Characteristical traits of the clinic and diagnosis of rheumatoid arthritis in early stages. Orig Med202211
     [Google Scholar]
  45. TuJ. ChenX. DaiM. PanA. LiuC. ZhouY. XiaX. SunL. Serum levels of 14-3-3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients.Exp. Ther. Med.202020275476110.3892/etm.2020.876132742321
     [Google Scholar]
  46. FanR. ZhouJ. XuY. GaoL. YuZ. ZangY. Serum 14-3-3η levels are increased and associated with a higher risk of osteoporosis in patients with rheumatoid arthritis: A meta-analysis.Exp. Ther. Med.20232727610.3892/etm.2023.1236438264428
     [Google Scholar]
  47. JahanT. Abu SalehA. AnwarS. AkhtarS. ChoudhuryR.M. Association of serum 14-3-3ƞ protein level in rheumatoid arthritis patients in a tertiary care hospital in Bangladesh.Fortune J. Health Sci.20236443844510.26502/fjhs.145
     [Google Scholar]
  48. AbdelhafizD. KilbornS. BukhariM. The role of 14-3-3 η as a biomarker in rheumatoid arthritis.Rheumatol. Immunol. Res.202122879010.2478/rir‑2021‑001236465971
     [Google Scholar]
  49. AwadA.S. AhmedY.A. Abd El Sattar El SerganyM. El Morsy El SayedS. Level of 14-3-3 (Eta) protein in rheumatoid arthritis patients.J. Adv. Med. Med. Res.2023354828910.9734/jammr/2023/v35i44961
     [Google Scholar]
  50. AdelY. SadeqY. 14-3-3η protein is associated with disease activity and osteoporosis in patients with rheumatoid arthritis.Reumatologia202260638439110.5114/reum.2022.12366936683839
     [Google Scholar]
  51. MohammedA.J. DiajilA.R. HassanF.I. Assessment of serum and salivary 14-3-3 ETA protein in rheumatoid arthritis patients. J. Res. Med. Dental Sci.20221010007
     [Google Scholar]
  52. AhmedS.A. DarwishE.M. AttyaW.A. SamirM. ElsayedM. AbbasH.M. HasanM.D. Anti-carbamylated protein antibodies and serum level of 14-3-3 protein for early detection of rheumatoid arthritis patient in correlation with rheumatoid factor, anti-CCP antibodies, disease activity and joint damage using high frequency musculoskeletal ultrasound.Appl. Clin. Res. Clin. Trials Regul. Aff.20207214115310.2174/2213476X07666200120111549
     [Google Scholar]
  53. FattahS.A. FattahM.A.A. MesbahN.M. SalehS.M. Abo-ElmattyD.M. MehannaE.T. YWHAH genetic variants are associated with increased hypoxia inducible factor-1α/vascular endothelial growth factor in Egyptian rheumatoid arthritis patients.Biochem. Genet.20226061986199910.1007/s10528‑022‑10202‑x35190930
     [Google Scholar]
  54. DammonaJ. ElzayatS. AlyH. GaafarA. Correlation between 14-3-3η protein and Muskelosketal ultrasound in early rheumatoid arthritis patients.Al-Azhar Int. Medical J.202010192-510.21608/aimj.2020.29538.1219
     [Google Scholar]
  55. HussinD.A.A.H. ShaatR.M. MetwallyS.S. AwadM. The significance of serum 14-3-3η level in rheumatoid arthritis patients.Clin. Rheumatol.20214062193220210.1007/s10067‑020‑05524‑333400046
     [Google Scholar]
  56. AliS. Role of 14-3-3η (Eta) protein as immunological marker for disease activity in patients with rheumatoid arthritis.Indian J. Public Health Res. Dev.2020112
     [Google Scholar]
  57. ChenJ. LiuH. Advances in biomarkers for rheumatoid arthritis.https://d197for5662m48.cloudfront.net/documents/citationstatus/225561/preprint_pdf/3c7d0ae08bf33c81f43c2a77a8f348ee.pdf202410.22541/au.172744212.23647466/v1
     [Google Scholar]
  58. MohammedS.A. SarhatE.R. Evaluation of serum Eta protein, sclerostin, and calcitonin level in arthritis patients on vitamin D therapy.Pharmacogn. J.202416242643010.5530/pj.2024.16.67
     [Google Scholar]
  59. WuY. DaiZ. WangH. WangH. WuL. LingH. ZhuY. YeD. WangB. Serum 14-3-3η is a marker that complements current biomarkers for the diagnosis of RA: Evidence from a meta-analysis.Immunol. Invest.202251118219810.1080/08820139.2020.181706932967487
     [Google Scholar]
  60. WangD. CuiY. LeiH. CaoD. TangG. HuangH. YuanT. RaoL. MoB. Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis.Int. J. Rheum. Dis.202023111443145110.1111/1756‑185X.1392132909672
     [Google Scholar]
  61. ColinaM. CampanaG. Precision medicine in rheumatology: The role of biomarkers in diagnosis and treatment optimization.J. Clin. Med.2025145173510.3390/jcm1405173540095875
     [Google Scholar]
  62. TrimovaG. YamagataK. IwataS. HirataS. ZhangT. UemuraF. SatohM. BilnN. NakayamadaS. MaksymowychW.P. TanakaY. Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages.Arthritis Res. Ther.20202212410.1186/s13075‑020‑2110‑931898524
     [Google Scholar]
  63. KiehstallerS. OttmannC. HennigS. MMP activation–associated aminopeptidase N reveals a bivalent 14-3-3 binding motif.J. Biol. Chem.202029552182661827510.1074/jbc.RA120.01470833109610
     [Google Scholar]
  64. WangQ. LiuY. WuJ. ChenS. HuT. LiuY. LiX. LiX. WuY. YuJ. ZengT. LuoY. HuX. TanL.M. Potential significance of changes in serum levels of IL-17, TNF-α and DKK-1 in the progression of the rheumatoid arthritis.Autoimmunity2023561227606810.1080/08916934.2023.227606837909152
     [Google Scholar]
  65. SamimiZ. KardidehB. ChalabiM. ZafariP. TaghadosiM. The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs).Braz. J. Pharm. Sci.202056e1855110.1590/s2175‑97902019000418551
     [Google Scholar]
  66. AbdelhadyE.I. TNF-α versus IL-6 genes expression levels in active rheumatoid arthritis: Clinical and laboratory determinants.Egypt. J. Immunol202330110
     [Google Scholar]
  67. SahinD. Di MatteoA. EmeryP. Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review.Ann. Clin. Biochem.202562132110.1177/0004563224128584339242085
     [Google Scholar]
  68. DingQ. HuW. WangR. YangQ. ZhuM. LiM. CaiJ. RoseP. MaoJ. ZhuY.Z. Signaling pathways in rheumatoid arthritis: Implications for targeted therapy.Signal Transduct. Target. Ther.2023816810.1038/s41392‑023‑01331‑936797236
     [Google Scholar]
  69. SuJ. HuW. DingY. ZhangP. LiT. LiuS. XingL. Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: A prospective observational cohort study.Arthritis Res. Ther.202426113010.1186/s13075‑024‑03373‑y38997725
     [Google Scholar]
  70. Koper-LenkiewiczO.M. SutkowskaK. Wawrusiewicz-KurylonekN. KowalewskaE. Matowicka-KarnaJ. Proinflammatory cytokines (IL-1,-6,-8,-15,-17,-18,-23, TNF-α) single nucleotide polymorphisms in rheumatoid arthritis—a literature review.Int. J. Mol. Sci.2022234210610.3390/ijms2304210635216226
     [Google Scholar]
  71. JangD. LeeA.H. ShinH.Y. SongH.R. ParkJ.H. KangT.B. LeeS.R. YangS.H. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics.Int. J. Mol. Sci.2021225271910.3390/ijms2205271933800290
     [Google Scholar]
  72. KondoN. KurodaT. KobayashiD. Cytokine networks in the pathogenesis of rheumatoid arthritis.Int. J. Mol. Sci.202122201092210.3390/ijms22201092234681582
     [Google Scholar]
  73. ÖnnheimK. HuangS. Strid HolmertzA. AnderssonS. LönnblomE. JonssonC. HolmdahlR. GjertssonI. Rheumatoid arthritis chondrocytes produce increased levels of pro-inflammatory proteins.Osteoarthritis. Cartilage Open20224110023510.1016/j.ocarto.2022.10023536474471
     [Google Scholar]
  74. FangQ. ZhouC. NandakumarK.S.J.M.o.i. Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis.Mediators Inflam2020202010.1155/2020/3830212
     [Google Scholar]
  75. JangS. KwonE.J. LeeJ.J. Rheumatoid arthritis: Pathogenic roles of diverse immune cells.Int. J. Mol. Sci.202223290510.3390/ijms2302090535055087
     [Google Scholar]
/content/journals/crr/10.2174/0115733971375944250811060418
Loading
Association of 14-3-3η with Tumor Necrosis Factor (TNF-α) and Matrix Metalloproteinase-1 (MMP-1) in Rheumatoid Arthritis
Curr. Rheumatol. Rev. 22, 104 (2026); https://doi.org/10.2174/0115733971375944250811060418
/content/journals/crr/10.2174/0115733971375944250811060418
/content/journals/crr/10.2174/0115733971375944250811060418
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): autoimmune disease; disease activity score; erythrocyte sedimentation rate; Rheumatoid arthritis; seronegative rheumatoid arthritis; seropositive rheumatoid arthritis; tumor necrosis factor alpha

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test